Call Options

2 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q4 2020

Feb 12, 2021

BUY
$37.09 - $48.97 $534,096 - $705,168
14,400 Added 73.1%
34,100 $1.27 Million
Q2 2020

Aug 12, 2020

BUY
$32.57 - $42.83 $641,629 - $843,751
19,700 New
19,700 $798,000

Others Institutions Holding FGEN

About FIBROGEN INC


  • Ticker FGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 93,741,200
  • Market Cap $32.8M
  • Description
  • FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...
More about FGEN
Track This Portfolio

Track Credit Suisse Ag Portfolio

Follow Credit Suisse Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.